Bioactivity | Sulfosuccinimidyl oleate (Sulfo-N-succinimidyl oleate) is a long chain fatty acid that inhibits fatty acid transport into cells. Sulfosuccinimidyl oleate is a potent and irreversible inhibitor of mitochondrial respiratory chain. Sulfosuccinimidyl oleate binds the CD36 receptor on the surface of microglia. Anti-inflammatory effect[1][2]. |
Invitro | Sulfosuccinimidyl oleate (20 μM and 50 μM, 24 hours) alone does not alter the cellular viability. Exposure to 100 ng/ml LPS+5 ng/mL IFNγ modestly, yet significantly reduces the viability of the BV2 cells. Co-treatment with Sulfosuccinimidyl oleate prevents the LPS+IFNγ-induced reduction in the cell viability[1]. Sulfosuccinimidyl oleate (50 μM, 24 hours) co-treatment significantly reduces the LPS+IFNγ-induced expression of NOS2 and COX-2 in BV2 cells. Western blot analysis reveals a significant LPS/IFNγ-induced upregulation in the phosphorylated form of the p38, which is prevented by co-treatment with Sulfosuccinimidyl oleate (50 μM, 24 hours)[1]. Cell Viability Assay[1] Cell Line: |
In Vivo | Sulfosuccinimidyl oleate (50 mg/kg; administered once by single oral gavage) significantly reduces the cortical ischemic infarct size compared to vehicle-treated controls in male BALB/cABom mice with pMCAo model. In addition, Sulfosuccinimidyl oleate at 50 mg/kg is suitable to see a beneficial effect after stroke[1]. Animal Model: |
Name | Sulfosuccinimidyl oleate |
CAS | 135661-44-8 |
Formula | C22H37NO7S |
Molar Mass | 459.60 |
Transport | Room temperature in continental US; may vary elsewhere. |
Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Reference | [1]. Dhungana H, et al. Sulfosuccinimidyl oleate sodium is neuroprotective and alleviates stroke-induced neuroinflammation. J Neuroinflammation. 2017 Dec 4;14(1):237. [2]. Drahota Z, et al. Succinimidyl oleate, established inhibitor of CD36/FAT translocase inhibits complex III of mitochondrial respiratory chain. Biochem Biophys Res Commun. 2010 Jan 15;391(3):1348-51. |